Abstracts Archive - Page 1067 of 2607 - ACR Meeting Abstracts

Abstract Number: 1903 • 2019 ACR/ARP Annual Meeting
BTK Overexpression Is Associated with the Risk of Lymphoma in Primary Sjögren’s Syndrome: Data from Whole Blood Transcriptome of 346 Patients Followed-up Prospectively for 10 Years
Pierre-Marie Duret¹, Tao Ye ², Wan-Fai Ng ³, Alain Saraux ⁴, Valérie Devauchelle Pensec ⁵, Raphaele Seror ⁶, Veronique Le-Guern ⁷, Claire Larroche ⁸, Aleth Perdriger ⁹, Jean Sibilia ¹⁰, Jessica Tarn ¹¹, Gaetane Nocturne ¹², Xavier Mariette ¹³ and Jacques-Eric Gottenberg ¹⁴, ¹Hôpitaux civils de Colmar, COLMAR CEDEX, France, ²GenomEAST platform / Institut National de la Santé et de la Recherche Médicale (INSERM), U1258, Institut de Génétique et de Biologie Moléculaire, IGBMC, Strasbourg, France, ³Musculoskeletal Research Group Institute of Cellular Medicine Faculty of Medical Sciences Newcastle University, Newcastle, United Kingdom, ⁴CHU de la Cavale-Blanche Brest, Brest, France, ⁵University Hospital of Brest, Brest, France, ⁶Hopitaux universitaires Paris Sud, Kremlin-Bicetre, France, ⁷Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP-HP, Université Paris Descartes, Paris, France,, Paris, France, ⁸Internal Medicine, Paris, France, Paris, France, ⁹Rheumatology department, Rennes University Hospital, France, Rennes, France, ¹⁰CHU Strasbourg, Strasbourg, France, ¹¹Institute of Cellular Medicine Newcastle University, Newcastle, United Kingdom, ¹²Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France., Paris, France, ¹³Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, ¹⁴Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France
Background/Purpose: To identify a molecular signature associated with lymphomagenesis in primary Sjögren’s Syndrome (pSS).Methods: Whole peripheral blood samples were collected from 346 well-phenotyped pSS patients…
Abstract Number: 1904 • 2019 ACR/ARP Annual Meeting
IL-6 Receptor Inhibition in Primary Sjögren Syndrome : Results from a Randomized Multicenter Academic Double Blind Placebo-controlled Trial of Tocilizumab in 110 Patients
Renaud Felten ¹, Nicolas Meyer ¹, P Duffaut ², D Saadoun ³, Eric Hachulla ⁴, Pierre Yves Hatron ⁴, Carine Salliot ⁵, Aleth Perdriger ⁶, Jacques Morel ⁷, Arsène Mekinian ⁸, Olivier Vittecoq ⁹, Jean Marie Berthelot ¹⁰, Emmanuelle Dernis ¹¹, Véronique Le Guern ¹², Philippe Dieudé ¹³, Claire Larroche ¹⁴, Christophe Richez ¹⁵, Thierry Martin ¹, Charles Zarnitsky ¹⁶, Gilles Blaison ¹⁷, P Kieffer ¹⁸, François Maurier ¹⁹, Stéphanie Rist ⁵, Patrice Cacoub ²⁰, Emmanuel Andres ²¹, Emmanuel Chatelus ¹, Christelle Sordet ¹, Jean Sibilia ¹, Cécile Arnold ¹, Mira Tawk ¹, Ouafaa Aberkane ¹, Raphaele Seror ²², Lise Holterbach ¹, Xavier Mariette ²² and Jacques-Eric Gottenberg²³, ¹Strasbourg University Hospital, Strasbourg, France, ²Bordeaux University Hospital, Bordeaux, Aquitaine, France, ³Pitie Salpetrière Hospital, APHP, Paris, France, ⁴Lille University Hospital, Lille, France, ⁵Orleans Hospital, Orleans, France, ⁶Rennes University Hospital, Rennes, France, ⁷Montpellier University Hospital, Montpellier, France, ⁸Saint-Antoine Hospital, APHP, Paris, France, ⁹Rouen University Hospital, ROUEN, France, ¹⁰Nantes University Hospital, Nantes, France, ¹¹Le Mans Hospital, Le Mans, France, ¹²Cochin Hospital, APHP, PARIS, France, ¹³Bichat Hospital, APHP, PARIS, ¹⁴Avicenne Hospital, PARIS, France, ¹⁵Bordeaux University Hospital, Bordeaux, France, ¹⁶Le Havre Hospital, Le Havre, ¹⁷Colmar Hospital, Colmar, France, ¹⁸Mulhouse Hospital, Mulhouse, France, ¹⁹Metz Hospital, Metz, France, ²⁰Pitie Salpéterière, APHP, Paris, France, ²¹CHU Strasbourg, strasbourg, ²²Bicetre Hospital, APHP, Paris, France, ²³Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France
Background/Purpose: IL-6 is suspected to play an important pathogenic role in primary Sjögren’s syndrome (pSS) through its crucial roles in B-cell activation, and T-cell polarization,…
Abstract Number: 1905 • 2019 ACR/ARP Annual Meeting
Sicca/Sjögren Syndrome Triggered by PD-1/PD-L1 Checkpoint Inhibitors: Data from the International ImmunoCancer Registry (ICIR)
Manuel Ramos-Casals ¹, Alexandre Maria ², Maria E. Suárez-Almazor ³, Olivier Lambotte ⁴, Benjamin A. Fisher ⁵, Gabriela Hernandez-Molina ⁶, Philippe Guilpain ², Xerxes Pundole ³, Soledad Retamozo⁷, Alejandra Flores-Chávez ⁸, Chiara Baldini ⁹, Clifton Bingham ¹⁰, Pilar Brito-Zerón ¹¹, Jacques-Eric Gottenberg ¹², Marie Kostine ¹³, Timothy R.D. Radstake ¹⁴, Thierry Schaeverbeke ¹⁵, Hendrik Schulze-Koops ¹⁶, Leonard Calabrese ¹⁷, Munther A Khamashta ¹⁸ and Xavier Mariette ¹⁹, ¹Department of Autoimmune Diseases, ICMiD. Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX. Department of Medicine, University of Barcelona, Hospital Clínic, Barcelona, Spain., Barcelona, Spain, ²Department of Internal Medicine, Multi-Organic Diseases, Local Referral Center for Autoimmune Diseases, Saint Eloi Hospital- Montpellier-1 University, Montpellier Cedex 5, France, Montpellier, France, ³Department of Rheumatology/Clinical Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX , USA., Houston, TX, ⁴APHP Médecine Interne/Immunologie Clinique, Hôpital Bicêtre, Paris, France. Université Paris Sud 11 – INSERM U1184 - CEA, Immunology of Viral Infections and Autoimmune Diseases, IDMIT Department, IBFJ, Fontenay-aux-Roses & Le Kremlin-Bicêtre, France., Paris, France, ⁵Institute of Inflammation and Ageing, University of Birmingham; and National Institute of Health Research Birmingham Biomedical Research Centre and Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK, Birmingham, United Kingdom, ⁶Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁷Instituto De Investigaciones En Ciencias De La Salud, Univ. Nacional de Córdoba, Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto Universitario de Ciencias Biomédicas de Córdoba, Córdoba, Argentina., Cordoba, Argentina, ⁸Department of Autoimmune Diseases, ICMiD, Barcelona, Spain., Barcelona, Spain, ⁹Rheumatology Unit, University of Pisa, Italy., Pisa, Italy, ¹⁰Johns Hopkins University, Baltimore, MD, ¹¹Sjögren Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX, Department of Autoimmune Diseases, ICMiD, University of Barcelona, Hospital Clínic. Autoimmune Diseases Unit, Department of Medicine, Hospital CIMA- Sanitas, Barcelona, Spain., Barcelona, Spain, ¹²Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹³Department of Rheumatology, Centre Hospitalier Universitaire, Bordeaux, France, Bordeaux, France, ¹⁴Department of Rheumatology/Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands., Utrecht, Netherlands, ¹⁵FHU ACRONIM, Department of Rheumatology, Centre Hospitalier Universitaire, Bordeaux, France, Bordeaux, France, ¹⁶Department of Rheumatology/Clinical Immunology, Ludwig-Maximilians-University Munich, Munich, Germany., Munich, Germany, ¹⁷Rheumatologic and Immunologic Disease/Cleveland Clinic, Cleveland, OH, ¹⁸King's College London School of Medicine, London, United Kingdom, ¹⁹Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France
Background/Purpose: To analyse the worldwide occurrence of sicca/Sjögren (SjS) syndrome associated with the use of immune checkpoint inhibitors (ICI) in patients with cancer.Methods: The ImmunoCancer…
Abstract Number: 1906 • 2019 ACR/ARP Annual Meeting
Using Multi-modal Ultrasound to Assess Disease Activity Within the Salivary Glands of Patients with Primary Sjögren’s Syndrome Treated with Ianalumab (VAY736)
Torsten Diekhoff ¹, Maximilian Posch ², Frank Wagner ², Thomas Fischer ¹, Quirino Schefer ², Thomas Dörner ³, Didier Laurent ⁴, Yue Li ⁴ and Stephen Oliver⁴, ¹Charité University Hospital, Berlin, Germany, ²Charité Research Organisation, Berlin, Germany, ³Charite Universitätsmedizin Berlin and DRFZ, Berlin, Germany, ⁴Novartis Pharma AG, Basel, Switzerland
Background/Purpose: To use ultrasound (US) to demonstrate that ianalumab, a monoclonal antibody with dual mechanisms-of-action of BAFF:BAFF-R blockade and enhanced, ADCC-mediated B cell depletion, can…
Abstract Number: 1907 • 2019 ACR/ARP Annual Meeting
Abatacept Reduces Serum CXCL13 and Disease-Relevant Immune Cell Phenotypes in a Double-Blind, Placebo-Controlled Primary Sjögren’s Syndrome Clinical Trial
Jacques-Eric Gottenberg¹, Sumanta Mukherjee ², Marleen Nys ³, Robert Wong ⁴, Hendrika Bootsma ⁵ and Neelanjana Ray ⁴, ¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Bristol-Myers Squibb, Princeton, NJ, ³Bristol-Myers Squibb, Braine L’Alleud, Belgium, ⁴Bristol-Myers Squibb, Princeton, ⁵University of Groningen, Groningen, Netherlands
Background/Purpose: Chemokine (C-X-C motif) ligand 13 (CXCL13), produced by follicular helper T (Tfh) cells, plays a pivotal role in B-cell homing and activation in germinal…
Abstract Number: 1908 • 2019 ACR/ARP Annual Meeting
Preliminary Identification of Arthritis-Associated Microbiota in Experimental Spondyloarthritis
Tejpal Gill¹, Tri Tran ², Stephen Brooks ³ and Robert Colbert ⁴, ¹NIAMS/NIH, Bethesda, MD, ²NIAMS, NIH, Bethesda, MD, ³Biomining and Discovery Section/NIAMS/NIH, Bethesda, MD, ⁴Pediatric Clinical Trials Unit, Pediatric Translational Research Branch, NIAMS, NIH, Bethesda, MD
Background/Purpose: Gut microbiota are strongly implicated in the pathogenesis of spondyloarthritis (SpA). Previous studies from our lab have documented extensive gut microbial dysbiosis in rats…
Abstract Number: 1909 • 2019 ACR/ARP Annual Meeting
miR-21-5p Expression as a Marker of Treatment Response in Psoriatic Arthritis Patients
Rohan Machhar¹, Justine (Yang) Ye ², Remy Pollock ¹ and Dafna Gladman ³, ¹Krembil Research Institute, University Health Network, Toronto, Canada, ²University Health Network, University of Toronto, Toronto, ON, Canada, ³Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis occurring in patients with psoriasis. Links between altered miRNA expression with the pathogenesis of several autoimmune disorders…
Abstract Number: 1910 • 2019 ACR/ARP Annual Meeting
Inflammatory Processes in Experimental Spondyloarthritis Are Accompanied by Formation of Ectopic Lymphoid Structures and B Cell Lineage Alterations in the Bone Marrow
Merlijn Kaaij¹, Jan Piet van Hamburg ¹, Jasper Rip ², George Kollias ³, Leonie van Duivenvoorde ¹, Martijn Nolte ⁴, Dominique Baeten ¹ and Sander Tas ¹, ¹Amsterdam Rheumatology & immunology Center, Amsterdam UMC/University of Amsterdam, Amsterdam, Netherlands, ²Department of Pulmonary Medicine, Erasmus MC, Rotterdam, Rotterdam, Netherlands, ³Division of Immunology, Biomedical Sciences Center ”Alexander Fleming”, Vari, Greece, Vari, Greece, ⁴Sanquin Research and Landsteiner Laboratory, Molecular & Cellular Hemostasis, Amsterdam UMC/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Tumour necrosis factor a (TNF) is important in immune-mediated inflammatory diseases such as spondyloarthritis (SpA). Transmembrane (tm)TNF-transgenic (tg) mice that overexpress tmTNF develop typical…
Abstract Number: 1911 • 2019 ACR/ARP Annual Meeting
Targeting the Oxidative Stress Pathway in Experimental Spondyloarthritis Reduces Pro-inflammatory Response in Rat Macrophages and Modulates Their Metabolic Requirements
Fatemeh Navid¹, Francesca LiCausi ¹, Breanna Nguyen ¹, Antony Cougnoux ², Pierre-Christian Violet ³, Mark Levine ³ and Robert Colbert ¹, ¹NIAMS/NIH, bethesda, ²NICHDR/NIH, Bethesda, ³NIDDK/NIH, Bethesda
Background/Purpose: HLA-B27 is associated with the development of spondyloarthritis (SpA) and has a tendency to generate ER stress due to misfolding which can activate the…
Abstract Number: 1912 • 2019 ACR/ARP Annual Meeting
High Dimensional Flowcytometric Profiling Distinguishes Psoriasis and Psoriatic Arthritis
Michelle Mulder¹, Juul van den Reek ², Elke de Jong ², Bram van Cranenbroek ², Ruben Smeets ², Irma Joosten ², Xuehui He ³, Frank van den Hoogen ¹, Hans Koenen ³ and Mark Wenink ¹, ¹Sint Maartenskliniek, Nijmegen, Netherlands, ²Radboudumc, Nijmegen, Netherlands, ³Radboudumc, Njimegen, Netherlands
Background/Purpose: Psoriasis (Pso) is a common chronic inflammatory skin disease. About 30% of Pso patients develop psoriatic arthritis (PsA), a chronic inflammation of joints and…
Abstract Number: 1913 • 2019 ACR/ARP Annual Meeting
Associations of HLA-B Alleles, Enthesitis and Peripheral Arthritis in Ankylosing Spondylitis
Benjamin Naovarat¹, Michael Weisman ², Lianne Gensler ³, Michael Ward ⁴, Mark Hwang ¹, Amirali Tahanan ¹, MinJae Lee ¹, Mohammad Rahbar ¹, Mariko Ishimori ⁵, Matthew Brown ⁶ and John Reveille ⁷, ¹University of Texas-McGovern Medical School, Houston, TX, ²David Geffen School of Medicine at UCLA, Los Angeles, CA, ³University San Francisco California, San Francisco, CA, ⁴NIAMS, Bethesda, MD, ⁵Cedars-Sinai Medical Center, Los Angeles, CA, ⁶Queensland University of Technology, Queensland, Australia, ⁷University of Texas McGovern Medical School, Houston
Background/Purpose: Recent studies have suggested that peripheral arthritis in patients with spondyloarthritis is associated with HLA-B*15. Studies of white patients with psoriatic arthritis (PsA) have…
Abstract Number: 1914 • 2019 ACR/ARP Annual Meeting
Increased Risk of Progression to Lupus Nephritis for Lupus Patients with Elevated Interferon Signature
Cristina Arriens¹, Quratul Raja ², Syed Ali Husain ², Bessy George ², Majid Abedi ³, Aviva Jacobs ⁴, Timothy Guyon ⁴, Hemani Wijesuriya ³, Teresa Aberle ⁵, Aikaterini Thanou ⁵, Stan Kamp ⁵, Susan R. Macwana ⁵, Eliza F. Chakravarty ¹, Joan T. Merrill ⁶, Judith James ¹, Robert Terbrueggen ⁴ and Joel Guthridge ¹, ¹Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³DxTerity Diagnostics Inc, Anaheim, CA, ⁴DxTerity Diagnostics Inc, Rancho Dominguez, CA, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Okalahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: The interferon (IFN) signature in SLE is well established, distinguishing lupus patients from healthy controls. Additionally, within lupus patients, higher levels of IFN-responsive gene…
Abstract Number: 1915 • 2019 ACR/ARP Annual Meeting
Validation of a Serologic Antibody Biomarker Against a Candidate Gut Pathobiont for the Diagnosis of Lupus Nephritis
Gregg Silverman¹, Doua Azzouz ¹, Caroline Grönwall ², Iva Gunnarsson ³ and Elisabet Svenungsson ⁴, ¹NYU School of Medicine, New York, NY, ²Rheumatology Unit, Department of Medicine, Karolinska University Hospital and Institutet, Stockholm, Sweden., Stockholm, Sweden, ³Karolinska Institute, Stockholm, Stockholms Lan, Sweden, ⁴Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Systemic lupus erythematosus (SLE) is the archetypic systemic autoimmune disease, for which there is mounting evidence for roles for intestinal bacteria in the development…
Abstract Number: 1916 • 2019 ACR/ARP Annual Meeting
Reduced DNASE1L3 Activity in Sporadic SLE Is Linked to Increased DNA Load of Microparticles, Reactivity to DNASE1L3-sensitive Antigens, and Lupus Nephritis
Johannes Hartl¹, Robert Clancy ¹, Peter Izmirly ¹, H Michael Belmont ², Catherine Trad ¹, Nicole Bornkamp ¹, Vanja Sisirak ¹, Benjamin Sally ¹, Jill Buyon ¹ and Boris Reizis ¹, ¹NYU School of Medicine, New York, ²NYU Langone Health, New York, NY
Background/Purpose: Null mutations in DNASE1L3 cause severe familial SLE with prominent anti-DNA antibodies (Abs), suggesting that DNASE1L3 is a key driver of tolerance to DNA.…
Abstract Number: 1917 • 2019 ACR/ARP Annual Meeting
Tubulointerstitial Inflammation Predicts Outcomes in Lupus Nephritis
Charles Oshinsky¹, Mariam Siddiqui ², Vladimir Liarski ³, Anthony Chang ³, Marcus Clark ⁴ and Kichul Ko ³, ¹University of Chicago, Department of Internal Medicine, Chicago, ²Northwestern Memorial Hospital, Chicago, ³University of Chicago, Chicago, ⁴University of Chicago, Chicago, IL
Background/Purpose: Lupus nephritis (LuN) causes significant morbidity and mortality, but predicting which patients will progress still remains imprecise. Current classification schema for LuN and its…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].